Arana Completes Series Of Humanised And Improved Antibodies For Vegenics’ Cancer Treatment Program

Antibody therapeutics company Arana Therapeutics Limited (ASX:AAH) and biologics drug development company Circadian Technologies Limited (ASX:CIR) today announced that Arana has successfully engineered an improved version of the VEGF-D antibody (VGX-200) owned by Circadian's 100% subsidiary Vegenics, for the treatment of solid cancers. Arana utilised its proprietary SuperhumanisationTM technology to successfully develop humanised versions of Vegenics' VEGF-D lead mouse antibody.